

Review

Anti-Inflammatory and Cytotoxic Activities of Clerodane-Type Diterpenes

Rubria Marlen Martínez-Casares ¹, Liliana Hernández-Vázquez ¹, Angelica Mandujano ²,
Leonor Sánchez-Pérez ², Salud Pérez-Gutiérrez ¹ and Julia Pérez-Ramos ^{1,*}

¹ Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Coyoacán 04960, CDMX, Mexico; rmartinezc@correo.xoc.uam.mx (R.M.M.-C.)

² Departamento de Atención a la Salud, Universidad Autónoma Metropolitana-Xochimilco, Calzada del Hueso 1100, Coyoacán 04960, CDMX, Mexico

* Correspondence: jperez@correo.xoc.uam.mx

Abstract: The secondary metabolites of clerodane diterpenoids have been found in several plant species from various families and in other organisms. In this review, we included articles on clerodanes and neo-clerodanes with cytotoxic or anti-inflammatory activity from 2015 to February 2023. A search was conducted in the following databases: PubMed, Google Scholar and Science Direct, using the keywords clerodanes or neo-clerodanes with cytotoxicity or anti-inflammatory activity. In this work, we present studies on these diterpenes with anti-inflammatory effects from 18 species belonging to 7 families and those with cytotoxic activity from 25 species belonging to 9 families. These plants are mostly from the Lamiaceae, Salicaceae, Menispermaceae and Euphorbiaceae families. In summary, clerodane diterpenes have activity against different cell cancer lines. Specific antiproliferative mechanisms related to the wide range of clerodanes known today have been described, since many of these compounds have been identified, some of which we barely know their properties. It is very possible that there are even more compounds than those described today, in such a way that makes it an open field to discover. Furthermore, some diterpenes presented in this review have already-known therapeutic targets, and therefore, their potential adverse effects can be predicted in some way.

Keywords: clerodane; neo-clerodane; anti-inflammatory; cytotoxic activities



Citation: Martínez-Casares, R.M.; Hernández-Vázquez, L.; Mandujano, A.; Sánchez-Pérez, L.; Pérez-Gutiérrez, S.; Pérez-Ramos, J. Anti-Inflammatory and Cytotoxic Activities of Clerodane-Type Diterpenes. *Molecules* **2023**, *28*, 4744. <https://doi.org/10.3390/molecules28124744>

Academic Editor: Domenico Trombetta

Received: 9 May 2023

Revised: 2 June 2023

Accepted: 9 June 2023

Published: 13 June 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Diterpenes are metabolites that come from isoprene units; these compounds can be classified according to their structure [1]. One type of diterpene is clerodanes, which are found in a wide range of plant species, especially those from the Labiatae, Euphorbiaceae and Verbenaceae families [2,3]; they have also been found in bacteria, fungi and marine sponges. This type of diterpene has been extensively studied due to many of them having biological activity [1–4]. For example, clerodin has anthelmintic activity [5]; salvinorin A is an agonist of κ -opioid receptor-serotonin-2A [6] with potential for use as a treatment in neuropsychiatric disorders [7]; tinosinenosides A–C show cytotoxicity effects against HeLa [8]; and columbin has anti-inflammatory and anticancer efficacy [4].

Clerodanes are secondary metabolites; when these compounds are obtained from plants, they are biosynthesized in the chloroplasts from geranylgeranyl pyrophosphate, producing a labdane-type precursor skeleton, which can be transformed to a halimane-type intermediate, and then converted to either *cis*- or *trans*- clerodanes [3] (Figure 1a).

Clerodanes are bicyclic diterpenoids with a fused ring of decalin structure (C₁–C₁₀) and a side chain of six carbons at C₉. They are classified according to the configuration at the ring fusion and the substituents in C₈ and C₉ into four types: *trans-cis*, *trans-trans*, *cis-cis* and *cis-trans* (Figure 1b). About 25% have a *cis* ring fusion, and 75% have 5:10 *trans* ring fusion [9].




Figure 1. (a) Biosynthesis of clerodanes and (b) general structure of clerodanes.

In this review, we have included clerodanes and *neo*-clerodanes and their enantiomers *ent-neo*-clerodanes (Figure 2). Additionally, carbons 12 to 16 are usually oxidized to diene, furan, lactone or hydrofurfuran, which give structural characteristics to clerodane [10].




Figure 2. Absolute clerodane configuration.

Cancer is a global health problem and is currently one of the main causes contributing to premature death worldwide [11]. At the present time, even with the great advances in medicine in our understanding and treatment of cancer with multimodal therapies including immunotherapy, gene-targeted therapy, chemotherapy, hormonal therapy and cancer vaccines [12] against specific cell targets, there are needs that have not been covered. These include more effective therapies, with fewer adverse effects, but also therapies at a more affordable cost. Thus, there is still a need to investigate more effective and less toxic compounds. Most of the chemotherapeutic drugs (nearly 65%) that are used in current cancer treatment regimens were originally isolated from natural products or their derivatives such as plants or microorganisms [13]. For instance, paclitaxel, a diterpene isolated from *Taxus brevifolia* (yew trees), classified as a taxane, is used in the therapy of various types of cancers [14]. Other examples include anthracyclines derived from

Streptomyces strains, among them being doxorubicin, bleomycin and many others [13]. The cytotoxic activity of several clerodanes in different cancer cell lines has been described [1].

On the other hand, inflammation is an immune response to different stimuli, such as pathogens such as viruses and bacteria, traumas and chemical irritants [15]; that is to say, inflammation is a protective response of the body against harmful stimuli. Additionally, long-term inflammation could lead to several symptoms, such as pain, fatigue, insomnia, depression and gastrointestinal problems [16]. Chronic inflammation is associated with diseases such as cancer, diabetes and arthritis [17]. The inflammatory response leads to the production of pro-inflammatory mediators, such as cytokines, serotonin, leukotrienes and histamine [18]. These mediators promote vascular permeability, leukocyte migration, blood vessel dilatation and pain. The anti-inflammatory activity of terpenes, such as carvacrol, some carotenes and diterpenes, such as clerodanes, and triterpenes, has been studied [2,19].

In this review, 158 clerodanes and 70 *neo*-clerodanes (1, 56, 57, 71–73, 94–132, 141–158, 184–187, 196, 197 and 207–210) with cytotoxic and anti-inflammatory activities reported from 2015 to February of 2023 were included. A total of 56 articles were found; in Table 1, the plants, family, collection place and part of the plants from which the clerodanes and *neo*-clerodanes were isolated are shown.

Table 1. Part of plant, family and collection place of plants that contained clerodanes or *neo*-clerodanes.

Plant	Family	Part of Plant	Collection Place
<i>Ajuga decumbens</i> [20]	Lamiaceae	Aerial parts	Pingtán island of Fujian Province.
<i>Anacolosia clarkia</i> [21]	Olacaceae	Fruit, leaves and twigs of the plant	Bana Forest Preserve in Danang, NCI Natural Products Repository.
<i>Casearia corymbosa</i> [22]	Salicaceae	Stem bark	Othón P. Blanco, Quintana Roo, Mexico.
<i>Casearia graveolens</i> [23]	Salicaceae	Twigs	Chiang Rai Province, northern Thailand.
<i>Casearia grewiifolia</i> [24,25]	Salicaceae	Fresh fruits	Khon Kaen University campus.
		Leaves	Phu Loc–Thua Thien Hue, Vietnam.
<i>Casearia kurzii</i> [26–29]	Salicaceae	Fruit, leaves and twigs	Bana Forest Preserve in Danang, Vietnam.
		Twigs and leaves	Xishuangbanna County, Yunnan Province, P. R. China.
<i>Casearia sylvestris</i> [30]	Salicaceae	Leaves	Parque Estadual Carlos Botelho (São Miguel Arcanjo, São Paulo State.)
<i>Croton caudatus</i> [31]	Euphorbiaceae	Leaves and twigs	Xishuangbanna Prefecture, Yunnan Province, P. R. China.
<i>Croton crassifolius</i> [32–34]	Euphorbiaceae	Roots	Yulin City, Guangxi Province, China.
			Southeast China, Thailand, Vietnam, and Laos.
			Fujian Province, People’s Republic of China.
<i>Croton echinoides</i> [35]	Euphorbiaceae	Stems	Brazil
<i>Croton oligandrus</i> [36]	Euphorbiaceae	Bark	Mount Eloundem, Central Region, Cameroon.
<i>Gottschelia schizopleura</i> [37]	Cephalozellaceae	Aerial parts	Mount Alab, Sabah, North Borneo, Malaysia.
<i>Laetia corymbulosa</i> [38]	Salicaceae	Bark	The plant was provided by NCI/NIH (Frederick, MD, U.S.).
<i>Linaria japonica</i> [39]	Plantaginaceae	Whole plants	Hiroshima, Japan.
<i>Polyalthia longifolia</i> [40]	Annonaceae	Seeds	Tirupati, India.
<i>Polyalthia laui</i> [41]	Annonaceae	Roots	Hainan Province, China.
<i>Salvia amarissima</i> [42–44]	Lamiaceae	Leaves and flowers	Teotihuacan, State of Mexico.
		Aerial portions	Teotihuacan Valley
<i>Salvia involucrata</i> [45]	Lamiaceae	Aerial parts	Municipality of Xilitla, State of San Luis Potosí, Mexico.
<i>Salvia leucantha</i> [46]	Lamiaceae	Aerial parts	Yunnan Province, China.

Table 1. Cont.

Plant	Family	Part of Plant	Collection Place
<i>Scutellaria barbata</i> [47–50]	Lamiaceae	Whole plant	Linyi district, Shandong Province, China.
		Aerial parts	Purchased in a drugstore of Liaoning Guodayizhi Pharmaceutical Co., Ltd. China.
		Aerial parts	Purchased from Bozhou Herbal Market in Anhui Province, China
<i>Scutellaria strigillosa</i> [51,52]	Lamiaceae	Whole plants	Yantai district, Shandong Province, China.
		Whole plants	Hebei, Shandong, Zhejiang and Jilin Provinces, China
<i>Sheareria nana</i> [53]	Asteraceae	Whole herb	Jishou, Hunan Province, China.
<i>Tinospora capillipes</i> [54]	Menispermaceae	Whole herb	Xishuangbanna County, Yunnan Province, China.
<i>Tinospora cordifolia</i> [55]	Menispermaceae	Stems	India
<i>Tinospora sagittata</i> [56]	Menispermaceae	Roots	Anguo Medicine market in Hebei Province, China.
<i>Ajuga reptans</i> [57,58]	Lamiaceae	Aerial parts	Yunnan Province, China.
		Aerial parts	Purchased from Anhui Province, China.
<i>Callicarpa arborea</i> [59]	Lamiaceae	Twigs	Xishuangbanna and Yuanyang Prefectures.
<i>Callicarpa cathayana</i> [60]	Lamiaceae	Dried aerial parts	Bozhou Herbal Market in Anhui Province, China.
<i>Callicarpa hypoleucophylla</i> [61]	Lamiaceae	Leaves and twigs	Kaohsiung city, Taiwan.
<i>Croton crassifolius</i> [32,62]	Euphorbiaceae	Roots	Guangxi Province, China.
<i>Croton floribundus</i> [63]	Euphorbiaceae	Roots	Provided by the company Mudas Nativas e Exóticas. LTDA of CNPJ, Araraquara Brazil.
<i>Croton laui</i> [64]	Euphorbiaceae	Leaves	Hainan Province, China.
<i>Croton poomae</i> [65]	Euphorbiaceae	Leaves and stems	Bung Kan Province, Thailand.
<i>Dodonaea viscosa</i> [66]	Sapindaceae	Leaves	Sierra de Huautla, Morelos State, Mexico.
<i>Dysoxylum lukii</i> . [67]	Meliaceae	Twigs and leaves	Xishuangbanna County, Yunnan Province, China.
<i>Jamesoniella autumnalis</i> [68]	Adelanthaceae	Whole plant	Wangtiane park, Changbaishan City, Jilin Province, China.
<i>Monoon membranifolium</i> [69]	Annonaceae	Twig extract	Thailand and Peninsula Malaysia.
<i>Nepeta suaveis</i> [70]	Lamiaceae	Roots	Found in central and southern Europe, North Africa and southern Asia.
<i>Polyalthia longifolia</i> [71]	Annonaceae	Seeds	Seshachalam hills, Tirupati, India.
<i>Scutellaria barbata</i> [72]	Lamiaceae	Aerial parts	Baise city, Guangxi Province, China.
<i>Teucrium fructicans</i> [73]	Lamiaceae	Aerial parts	Jiansu Province, China.
<i>Tinospora crispa</i> [74,75]	Menispermaceae	Stems	Mengla County, Yunnan Province, China.
		Vines and leaves	Longzhou County, Guangxi Province, China.
<i>Tinospora sagittata</i> [76]	Menispermaceae	Tuberous roots	Shiyan city of Hubei Province, China.

Clerodanes and *neo*-clerodanes with cytotoxic activity are shown in Table 2, and their structures are shown in Figures 3–13.

Table 2. Clerodane diterpenes with cytotoxic activity.

Plant Source	Compound Name	Methods	Results	References
<i>Ajuga decumbens</i>	Compound 1	CCK8 method	IC ₅₀ μM	[20]
		A549 HeLa	71.4 71.6	
	Ajugamarin A1 (2)	A549 HeLa	76.7 5.39 × 10 ⁻⁷	

Table 2. Cont.

Plant Source	Compound Name	Methods	Results	References	
<i>Anacolosia clarkii</i>	Anacolosin A (3)	SRB assay	TGI μ M	[21]	
		A-673	1.10		
		SJCRH30	0.52		
		D283	0.70		
	Anacolosin B (4)	Hep293TT	1.00		
		A-673	1.00		
		SJCRH30	0.50		
		D283	0.60		
	Anacolosin C (5)	Hep293TT	0.90		
		A-673	1.10		
		SJCRH30	0.67		
		D283	0.66		
Anacolosin D (6)	Hep293TT	1.00			
	A-673	1.20			
	SJCRH30	0.73			
	D283	0.66			
Anacolosin E (7)	Hep293TT	0.80			
	A-673	3.10			
	SJCRH30	1.90			
	D283	2.00			
Anacolosin F (8)	Hep293TT	1.80			
	A-673	4.10			
	SJCRH30	2.30			
	D283	2.30			
Corymbulosin X (9)	Hep293TT	3.20			
	A-673	0.70			
	SJCRH30	0.34			
	D283	0.36			
Corymbulosin Y (10)	Hep293TT	0.22			
	A-673	1.00			
	SJCRH30	0.44			
	D283	0.70			
Compound 11	Hep293TT	0.28			
	A-673	1.70			
	SJCRH30	0.80			
	D283	1.10			
Caseamembrin S (12)	Hep293TT	0.60			
	A-673	0.90			
	SJCRH30	0.36			
	D283	0.50			
<i>Casearia corymbosa</i>	Hep293TT	0.30			
	SRB assay	CC ₅₀ μ M (SI)	[22]		
	HeLa	13.44			
	SiHa	77.36			
Vero	50.26				
<i>Casearia graveolens</i>	Caseariagraveolin (14)	REMA assay	IC ₅₀ μ M	[23]	
		KB	2.48		
		MCF-7	6.63		
		MTT assay	IC ₅₀ μ g/mL		
<i>Casearia grewiifolia</i>	Caseargrewiin M (15)	BT474	6.30	[24,25]	
		Chago-K1	6.10		
		Hep-G2	4.64		
		KATO-III	5.50		
		SW620	5.50		
		Caseargrewiin G (16)	BT474		5.67
	Chago-K1		6.10		
	Hep-G2		0.90		
	KATO-III		5.46		
	SW620		3.85		
	Caseargrewiifolin B (17)		WST-1 assay		IC ₅₀ μ M
		KB	6.2		
Hep-G2		7.0			
Caseanigrescen D (18)		KB	0.5		
	Hep-G2	0.3			
	LU-1	0.9			
	MCF-7	0.8			
	NIH-3T3	0.3			

Table 2. Cont.

Plant Source	Compound Name	Methods	Results	References	
<i>Casearia kurzii</i>	Kurziterpene A (19)	MTT assay	IC ₅₀ μM		
		A549, HeLa, HepG ₂	40.8, >60, >60		
		Kurziterpene B (20)	A549	19.7	
			HeLa	12.1	
			Hep-G2	49.3	
	Kurziterpene C (21)	A549, HeLa, Hep-G2	>60, 49.4, >60		
		Kurziterpene D (22)	A549, HeLa, Hep-G2	18.3, 9.0, >60	
			Kurziterpene E (23)	A549, HeLa, Hep-G2	10.2, 5.3, 10.7
	Analysis via flow cytometry			Apoptosis of HeLa	
	(2R,5S,6S,8R,9R,10S,18S,19S)-2,19-diacetoxy-6,18-dimethoxy-18,19-epoxycyclohexa-3,13(16),14-triene (24)	MTT assay		IC ₅₀ μM	
		A549, HeLa, Hep-G2	>60, 17.9, >60		
		Corymbulosin M (25)	A549, HeLa, Hep-G2	5.5, 4.1, 9.3	
			Analysis via flow cytometry		Apoptosis of HeLa
	Caseamembrin B (26)		MTT assay	IC ₅₀ μM	
		A549, HeLa, Hep-G2	36.1, 18.8, >60		
		Caseamembrin U (27)	A549, HeLa, Hep-G2	33.2, 15.6, >60	
	Caseakurzin A (28)		QIR assay	IC ₅₀ μM	[26–29]
			A549	10.8	
	Caseakurzin B (29)	QIR assay	IC ₅₀ μM		
		A549	4.4		
			Cell apoptosis assay	Apoptosis of A549	
	Caseakurzin C (30)			IC ₅₀ μM	
				30.3	
	Caseakurzin D (31)	QIR assay		27.8	
	Caseakurzin E (32)	A549		32.7	
	Caseakurzin F (33)			26.8	
	Caseakurzin J (34)	QIR assay	IC ₅₀ μM		
A549		4.6			
		Cell apoptosis assay	Apoptosis of A549		
Kurzipene A (35)	MTT assay	IC ₅₀ μM			
	Hep-G2, A549, HeLa, K562	>60, >60, >60, >60			
	Kurzipene B (36)	Hep-G2, A549, HeLa, K562	>60, 32.6, 54.6, >60		
		Kurzipene C (37)	Hep-G2, A549, HeLa, K562	>60, >60, >60, >60	
			Kurzipene D (38)	Hep-G2, A549, HeLa, K562	9.7, 10.9, 12.4, 7.2
Flow cytometry				Apoptosis of Hep-G2	
Anti-tumor assay using zebrafish model				It blocked tumor cell invasion and metastasis	

Table 2. Cont.

Plant Source	Compound Name	Methods	Results	References
	Kurzipene E (39)	Hep-G2	>60	
		A549	>60	
		HeLa	>60	
		K562	>60	
	Kurzipene F (40)	Hep-G2	>60	
		A549	>60	
		HeLa	33.1	
		K562	>60	
	Corymbulosin V (41)	Hep-G2	16.8	
		A549	11.2	
		HeLa	14.2	
		K562	10.3	
	Corymbulosin M (25)	Hep-G2	20.6	
		A549	18.4	
		HeLa	17.5	
		K562	16.5	
<i>Casearia sylvestris</i>	Casearin X (42)	Induced sarcoma tumor 25 mg/kg/day	Tumor inhibition % 90.0	[30]
<i>Croton caudatus</i>	Crocleropene A (43)	MTT assay MCF-7	IC ₅₀ μM 35.8	[31]
	Crocleropene B (44)	MCF-7	40.2	
<i>Croton crassifolius</i>	Crassifolius A (45)	Morphology	Induced apoptosis	[32–34]
		Western blot	Caspase activation	
	Crassifolius A (45)	MTT assay Hep3B	IC ₅₀ μM 17.91	
		Hep-G2	42.04	
	Crassifolin C (46)	Hep-G2	51.63	
	Compound 47	Hep-G2	45.22	
	Crassifolin B (48)	CT26.WT	96.6	
	Crassifolin Q (49)			
	Crassifolin R (50)	HUVEC assay	Compounds 49–51 and 53 inhibited angiogenesis	
	Crassifolin S (51)			
Crassifolin T (52)	HUVEC assay	Anti-angiogenesis effect		
Crassifolin U (53)	HUVEC assay Junction densities Vessel areas Vessel lengths	IC ₅₀ μM 7.20 48.27 8.62		
<i>Croton echinoides</i>	CEH-1 (54)	MTT assay HTC	Compound 54 diminished 67% cell viability and 55 < 76%.	[35]
	CEH-4 (55)			
<i>Croton oligandrus</i>	Megalocarpoidolide D (56)	MTT assay A549 MCF-7	IC ₅₀ μM 63.8 136.2	[36]
	12-epi-megalocarpoidolide D (57)	A549 MCF-7	138.6 171.3	
<i>Gottschelia schizopleura</i>	Schizopleurolide A (58)	MTT assay HL-60 B16-F10	IC ₅₀ μM 38.47 47.25	[37]
	Schizopleurolide B (59)	HL-60 B16-F10	36.13 44.33	

Table 2. Cont.

Plant Source	Compound Name	Methods	Results	References
<i>Laetia corymbulosa</i>	Corymbulosin I (60)	Flow cytometry	Compounds 60, 61, 12 and 11 induced apoptosis in MDA-MB-231	[38]
		SRB assay	IC ₅₀ μM	
		A549	0.66	
		MDA-MB-231	0.48	
		MCF-7	0.68	
	Corymbulosin K (61)	KB	0.56	
		KB-VIN	0.98	
		A549	0.47	
		MDA-MB-231	0.49	
		MCF-7	0.50	
	Corymbulosin L (62)	KB	0.45	
		KB-VIN	0.49	
		A549	4.60	
		MDA-MB-231	4.95	
		MCF-7	4.94	
	Corymbulosin N (63)	KB	5.19	
		KB-VIN	4.92	
		A549	5.04	
		MDA-MB-231	4.90	
		MCF-7	5.82	
Corymbulosin O (64)	KB	5.23		
	KB-VIN	5.19		
	A549	4.75		
	MDA-MB-231	3.31		
	MCF-7	4.65		
Corymbulosin P (65)	KB	4.25		
	KB-VIN	4.76		
	A549	5.98		
	MDA-MB-231	4.93		
	MCF-7	6.39		
Corymbulosin Q (66)	KB	5.16		
	KB-VIN	5.03		
	A549	40.2		
	MDA-MB-231	20.5		
	MCF-7	31.7		
Corymbulosin S (67)	KB	19.8		
	KB-VIN	39.2		
	A549	>40		
	MDA-MB-231	22.9		
	MCF-7	26.2		
Corymbulosin T (68)	KB	25.1		
	KB-VIN	26.6		
	A549	2.29		
	MDA-MB-231	0.49		
	MCF-7	0.69		
Corymbulosin V (41)	KB	0.56		
	KB-VIN	0.61		
	A549	4.76		
	MDA-MB-231	4.73		
	MCF-7	5.19		
Caseamembrin S (12)	KB	4.74		
	KB-VIN	4.88		
	A549	0.58		
	MDA-MB-231	0.45		
	MCF-7	0.66		
Caseamembrin E (69)	KB	0.53		
	KB-VIN	0.90		
	A549	0.53		
	MDA-MB-231	0.40		
	MCF-7	0.55		
Corymbulosin A (70)	KB	0.43		
	KB-VIN	0.51		
	A549	0.45		
	MDA-MB-231	0.43		
	MCF-7	0.44		
		KB	0.42	
		KB-VIN	0.45	

Table 2. Cont.

Plant Source	Compound Name	Methods	Results	References
	Compound 11	A549 MDA-MB-231 MCF-7 KB KB-VIN	4.15 0.54 0.89 0.73 4.07	
<i>Linaria japonica</i>	Linarenone C (71)	MTT assay A549	IC ₅₀ μM 51.2	[39]
	Linarenone E (72)		86.5	
	Linarienone (73)		79.0	
<i>Polyalthia longifolia</i>	16-hydroxy-cleroda-4(18),13-dien-16,15-olide (74)	Evaluation of morphometric liver and biochemical parameters in (NDEA+PB)-induced HCC rats	Compound 75 and 77 restored the parameters' biochemical and liver morphology	[40]
		MTT assay Hep-G2	IC ₅₀ μg/mL 34.33	
	3α,16α-dihydroxy-cleroda-4(18),13(14)Z-dien-15,16-olide (75)	Hep-G2 HuH-7	14.34 47.32	
	16α-hydroxy-cleroda-3,13(14)Z-dien-15,16-olide (76)	Hep-G2	29.21	
	3β-16a-dihydroxy-cleroda-4(18),13(14)Z-dien-15,16-olide (77)	Hep-G2 HuH-7	24.91 48.57	
<i>Polyalthia laui</i>	Polylauriester A (78)	MTT assay HeLa MCF-7 A549	IC ₅₀ μM 34.84 33.21 35.65	[41]
	(4→2)-abeo-2,13-diformyl-cleroda-2,12E-dien-14-oic acid (79)	HeLa MCF-7 A549	39.31 37.35 37.82	
	Polylauriamide B (80)	HeLa MCF-7 A549	28.09 29.16 29.25	
	Polylauriamide C (81)	HeLa MCF-7 A549	25.01 30.30 28.65	
	Polylauriamide D (82)	HeLa MCF-7 A549	26.73 27.03 28.88	
		Teotihuacanin (83)	SRB assay MDA-MB-231 HeLa HCT-15 HCT-116 MCF-7	
<i>Salvia amarissima</i>	Amarissinin A (84)	MCF-7 MCF-7/Vin ⁺ MDA-MB-231 HeLa	18.2 0.27 19.3 14.0	[42–44]
	Amarissinin B (85)	SRB assay	83, 84, 85, 86 and 87 exhibited MDR modulatory effects in mammalian cancer cells	
	Amarissinin C (86)			
		Amarisolide F (87)	SRB assay MCF-7 HeLa HCT-15 HCT-116 MDA-MB-231	IC ₅₀ μM 42.1 >42 >42 >42 >42

Table 2. Cont.

Plant Source	Compound Name	Methods	Results	References
<i>Salvia involucrata</i>	Involucratin A (88)	U251	49.6	[45]
		PC-3	14.7	
		K562	24.8	
		SKLU-1	12.6	
	Involucratin B (89)	U251	5.1	
		PC-3	23.5	
		K562	34.7	
		HCT-15	11.8	
		MCF-7	0.5	
		SKLU-1	36.7	
Involucratin C (90)	PC-3	11.0		
	K562	19.4		
	HCT-15	9.7		
	SKLU-1	16.8		
(-)-Hardwickiic acid (91)	COS-7	11.9		
	U251	22.4		
	PC-3	1.8		
	K562	45.5		
	HCT-15	10.4		
	MCF-7	1.4		
7 α -hydroxybacchotricuneatin A (92)	SKLU-1	11.5		
	COS-7	19.8		
	U251	3.8		
	PC-3	12.8		
	K562	20.2		
	HCT-15	13.3		
Kingidiol (93)	SKLU-1	33.0		
	COS-7	14.2		
	SRB assay	IC ₅₀ μ M		
	U251	22.4		
	PC-3	13.0		
	K562	51.6		
	HCT-15	15.5		
	MCF-7	0.8		
<i>Salvia leucantha</i>	Salvileucantholide (94)	SKLU-1	22.9	[46]
		COS-7	19.7	
		MTT assay	IC ₅₀ μ M	
		HCT-116	32.61	
		BT474	25.02	
<i>Scutellaria barbata</i>	Scubatine A (95)	HepG2	37.35	[47–50]
		A549	6.78	
		HL-60	>20	
	Scubatine B (96)	A549	>20	
		HL-60	>20	
	Scubatine C (97)	A549	>20	
		HL-60	>20	
	Scubatine D (98)	A549	>20	
		HL-60	>20	
	Scubatine E (99)	A549	>20	
		HL-60	>20	
	Scubatine F (100)	A549	15.3	
		HL-60	10.4	
	Scutebata E (101)	MTT assay	IC ₅₀ μ M	
		HL-60	>20	
A549		>20		
Scutolide K (102)	LoVo	61.23		
	HL-60	>20		
Scutebata X (103)	A549	>20		
	SGC-7901	>40		
	MCF-7	37.2		
Scutebata Y (104)	A549	>40		
	SGC-7901	>40		
	MCF-7	>40		
Scutebata Z (105)	A549	>40		
	SGC-7901	>40		
	MCF-7	>40		

Table 2. Cont.

Plant Source	Compound Name	Methods	Results	References
	Scutebata A ₁ (106)	SGC-7901 MCF-7 A549	>40 >40 35.5	
	Scutebata B ₁ (107)	SGC-7901 MCF-7 A549	>40 >40 >40	
	Scutebata C ₁ (108)	SGC-7901 MCF-7 A549	17.9 29.9 35.7	
	Barbatin H. (109)	LoVo MCF-7 SMMC-7721 HCT-116	32.44 49.86 48.75 44.24	
	Scuterbarbatine F (110)	LoVo MCF-7 SMMC-7721 HCT-116	23.32 49.19 58.12 78.83	
	6-O-nicotinoylscutebarbatine G (111)	LoVo SMMC-7721 HCT-116	29.44 65.51 54.44	
	Scutebata G (112)	LoVo MCF-7 SMMC-7721 HCT-116	22.56 31.33 32.49 28.29	
	Scutebata D (113)	LoVo MCF-7 SMMC-7721 HCT-116	20.75 31.42 29.24 62.66	
	Barbatin C (114)	LoVo MCF-7 SMMC-7721 HCT-116	37.99 28.06 72.69 32.94	
	Scutebarbatine A (115)	LoVo	67.77	
	Scutebarbatine G (116)	LoVo SMMC-7721 HCT-116	56.46 70.16 44.25	
	6,7-di-O-acetoxybarbatin A (117)	LoVo MCF-7 SMMC-7721 HCT-116	60.33 37.31 77.93 32.28	
	Scutebarbatine X (118)	LoVo MCF-7 SMMC-7721 HCT-116	43.21 74.83 46.14 62.11	
	Barbatin F (119)	LoVo HCT-116	56.46 44.25	
	Barbatin G (120)	LoVo SMMC-7721 MCF-7 HCT-116	60.33 37.31 77.93 32.28	
	Scutebata A (121)	LoVo SMMC-7721 MCF-7 HCT-116 HL-60 A549	4.57 7.68 5.31 6.23 >20 >20	
	Scutebata B (122)	LoVo SMMC-7721 MCF-7 HCT-116	10.73 18.96 10.27 28.48	
	Scutebata C (123)	LoVo SMMC-7721 MCF-7	47.15 33.18 38.79	
	Scutebata P (124)	LoVo SMMC-7721 MCF-7 HCT-116 HL-60 A549 HCT-116	15.17 42.63 32.49 23.97 5.6 21.7 23.97	

Table 2. Cont.

Plant Source	Compound Name	Methods	Results	References
<i>Scutellaria strigillosa</i>	Scutestrigillosin A (125)	REMA assay	IC ₅₀ μM	[51,52]
		P-388	5.8	
		HONE-1, HT-29	3.5 4.7	
		MCF-7	5.7	
	Scutestrigillosin B (126)	P-388	5.2	
		HONE-1 HT-29	4.2 4.1	
		MCF-7	6.0	
	Scutestrigillosin C (127)	P-388	7.1	
		HONE-1, HT-29	3.9 6.4	
		MCF-7	7.7	
Scutestrigillosin D (128)	P388	5.6		
	HONE 1 HT-29	3.4 4.7		
	MCF-7	5.2		
Scutestrigillosin E (129)	P388	8.9		
	HONE 1 HT-29	7.3 8.1		
	MCF-7	7.4		
<i>Sheareria nana</i>	Sheareria A (130)	CCK8 assay	IC ₅₀ μM	[53]
		HeLa	11.6	
		PANC-1 A549	7.1 9.3	
	Sheareria B (131)	HeLa	9.4	
		PANC-1 A549	5.6 6.8	
	Sheareria C (132)	HeLa PANC-1 A549	17.2 9.8 12.5	
<i>Tinospora cordifolia</i>	Tinocapillin A (133)	MTT assay	IC ₅₀ μM	[54]
		A549	14.0	
		HepG2	9.9	
		HeLa	9.7	
		OS-RC-2	10.6	
	Tinocapillin B (134)	A549	9.6	
		HepG2	10.1	
		HeLa OS-RC-2	12.0 19.1	
	Tinocapillin C (135)	A549	53.2	
		HeLa	67.5	
Tinocallone A (136)	A549	67.8		
	HepG2	68.4		
	HeLa	79.3		
Tinocallone C (137)	A549	16.3		
	HepG2	13.8		
	HeLa	17.5		
	OS-RC-2	12.8		
Columbin (138)	A549	77.3		
	HeLa	58.4		
<i>Tinospora capillipes</i>	ECD (epoxy clerodane diterpene) (139)	MTT assay	IC ₅₀ μM	[55]
		V79	52.7	
		MCF-7 Vero	3.2 45.8	
		qPCR analysis	Inhibited MCF-7 grow by regulation the expression of genes such Cdkn2A, Rb1, Mdm2 y p53	
<i>Tinospora sagittata</i>	Tinosporin A (140)	MTT assay HL-60 MCF-7	IC ₅₀ μM 18.63 23.58	[56]

Compound 1 (1*S*,4*aS*,5*R*,6*S*,8*R*,8*aS*)-8-acetoxy-5-((*R*)-2-acetoxy-2-(5-oxo-2,5-dihydrofuran-3-yl)ethyl)-2-hydroxy-5,6-dimethyloctahydro-8*aH*-spiro[naphthalene-1,2'-oxiran]-8*a*-yl)methyl (E)-2-methylbut-2-enoate; Compound 11 (2*R*,5*S*,6*S*,8*R*,9*R*,10*S*,18*R*,19*S*)-18,19-di-*O*-acetyl-18,19-epoxy-6-hydroxy-2-(2'-methylbutanoyloxy)cleroda-3,13-(16),14triene; Compound 47 6-[2-(furan-3-yl)-2-oxoethyl]-1,5,6-trimethyl-10-oxatricyclo[7.2.1.0^{2,7}] dodec-2(7)-en-11-one. 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT); sulforhodamine B (SRB); *N*-nitrosodiethylamine and phenobarbital sodium (NDEA+PB); cell counting kit 8 assay (CCK8); resazurin microplate assay (REMA); protein 90 kDa of family of chaperones (Hsp90); concentration cytotoxic at 50% (CC₅₀); quinone reductase assay (QIR); selective index (SI); total growth inhibitory (TGI); breast cancer (MCF-7); breast cancer

resistant at vinblastine (MCF-7/Vin); breast ductal carcinoma (BT474); cervix adenocarcinoma (HeLa); cervix squamous carcinoma (SiHa); colon adenocarcinoma (SW620, HCT-15, HCT-116 and HT-29) colon cancer (LoVo); chronic myeloid leukemia (K562); epidermoid carcinoma of the nasopharynx (KB); Ewing sarcoma (A-673); gastric carcinoma (KATO-III, SGC-7901); glioblastoma (U251); hepatocarcinoma (Hep293TT, Hep3B, Hep-G2, SMMC-7721, HCC, HuH-7); human umbilical vein endothelial cells (HUVEC); liver tumor cells of *Rattus norvegicus* (HTC); lymphoma cells (P388); lung adenocarcinoma (LU-1, SKLU-1, A549); medulloblastoma (D283); mouse colon adenocarcinoma (CT26.WT); mouse embryonic fibroblast cell line (NIH-3T3); musculus skin melanoma (B16-F10); normal green monkey kidney cell line (Vero); normal monkey kidney (COS-7); normal prostate epithelium (PNT2); promyelocytic leukemia (HL-60); prostate cancer (PC-3); P-gp-overexpressing MDR subline of KB (KB-VIN); pancreatic carcinoma (PANC-1); renal carcinoma (OS-RC-2); rhabdomyosarcoma (SJCRC30); triple-negative breast cancer (MDA-MB-231); two epithelial tumor cell lines (HNE-1 and HONE-1); undifferentiated lung carcinoma (Chago-K1).




Figure 3. Isolated compound of *Ajuга decumbens* and *Anacolosа clarkii*.




Figure 4. Isolated compounds of different species of *Casearia*.




Figure 5. Isolated compounds of different species of *Casearia* (continued).




Figure 6. Isolated compounds of different species of *Croton*.




Figure 7. Isolated compounds of *Gottschelia schizopleura* and *Laetia corymbulosa*.




Figure 8. Isolated compounds of *Linaria japonica* and *Polyalthia longifolia*.




Figure 9. Isolated compounds of different species of *Salvia*.






Figure 10. Cont.

Figure 10. Isolated compounds of *Scutellaria barbata* (continued).Figure 11. Isolated compounds of *Scutellaria barbata*.




Figure 12. Isolated compounds of *Scutellaria strigillosa*.




Figure 13. Isolated compounds of *Sheareria nana*, *Tinospora capillipes*, *Tinospora cordifolia* and *Tinospora sagittata*.

Clerodanes and neo-clerodanes' anti-inflammatory activities are summarized in Table 3, and their structures are shown in Figures 14–19.

Table 3. Clerodane diterpenes with anti-inflammatory activity.

Plant Source	Compound Name	Methods	Results	References
<i>Ajuga pantantha</i>	Ajugapantin C (141)	Western Blot Analysis	Compounds 141, 142 and 146 downregulated iNOS and COX-2 protein levels	[57,58]
		Docking Analysis	Compounds 141, 142 and 146 have strong interactions with the iNOS and COX-2 proteins	
		Griess assay BV-2 cells stimulated LPS	IC ₅₀ μM 20.2	
	Ajugapantin E (142)	Griess assay BV-2 cells stimulated LPS	IC ₅₀ μM 45.5	
	Ajugapantin F (143)		34.0	
	Ajugapantin G (144)		27.0	
	Ajugapantin H (145)		45.0	
	Ajugapantin I (146)		25.8	
	Pantanpene α (147)		IC ₅₀ μM 65.7	
	Pantanpene B (148)		37.7	
	Pantanpene C (149)		61.7	
	Pantanpene d (150)	>50% inhibition at 30 μM		
	Pantanpene E (151)	Griess assay BV-2 cells stimulated LPS	IC ₅₀ μM 21.7	
Anti-inflammatory assay in zebrafish model		The anti-inflammatory effect was confirmed		
<i>Callicarpa arborea</i>	Callicarpin A (152)	Docking Analysis	Compounds 148 and 151 have strong interactions with the iNOS and COX-2 proteins	
		IC ₅₀ μM 16.6		
		Callicarpin B (153)	4.0	
		Callicarpin C (154)	25.4	
		(16S)-Tris-O-Acetylcallicarpin C (155)	5.3	
		Callicarpin E (156)	24.7	
	Callicarpin F (157)	1.5		
Callicarpin G (158)	NLRP3 Inflammasome activation assay J774A.1 cells were primed with LPS	IC ₅₀ μM 1.4		
<i>Callicarpa cathayana</i>	Cathayanalactone A (159)	Pyroptosis fluorescence microscopy	The compound 153 inhibited pyroptosis and blocked NLRP3 inflammasome activation by hampering Casp-1 cleavage and IL-1β secretion	
		Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μM 22.92	
	Cathayanalactone B (160)	13.25		
	Cathayanalactone C (161)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μM 82.82	
	15-methoxyptagonic acid (162)	35.35		
	16-hydroxycleroda-3, 13-dien-16, 15-olide-18-oic acid (163)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μM 17.49	
	ELISA assay Quantification of TNF-α, IL-6 and IL-1β	Compounds 161–163 inhibited IL-1β, IL-6 and TNF-α		

Table 3. Cont.

Plant Source	Compound Name	Methods	Results	References	
<i>Callicarpa hypoleucophylla</i>	Callihypolin A (164)	Inhibitory activities in - superoxide anion generation and - elastase release in formyl-methionyl-leucyl- phenylalanine (fMLF)/cytochalasin (CB)-induced human neutrophils	% of inhibition 20.28 8.26	[61]	
	Callihypolin B (165)		31.19 17.55		
	Compound 166		31.19 12.15		
	Patagonic acid (167)		32.88 13.57		
	Limbatolide F (168)		23.65 7.33		
	Limbatolide A (169)		8.44 10.50		
	Compound 170		7.93 9.30		
	Clerodermic acid (171)		15.23 11.80		
	Visclerodol acid (172)		18.80 16.30		
<i>Croton crassifolius</i>	Crassifolin Q (49)	ELISA assay IL-6 TNF- α	% of production 72.23 89.38	[32,62]	
	Crassifolin R (50)		77.88 77.73		
	Crassifolin S (51)		73.36 79.23		
	Crassifolin T (52)		35.48 54.14		
	Crassifolin U (53)		32.78 12.53		
	Compound 173		IC ₅₀ μ M 25.8		
	Compound 174		Griess assay RAW264.7 macrophages stimulated LPS		173 at 178 < 50% inhibition at 50 μ M
	C-6 epimer of crotoeuricin C (175)				
	Crotocaudin (176)				
Teucvin (177)					
Crassifolin F (178)					
<i>Croton floribundus</i>	Croflorin A (179)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μ M 28.52	[63]	
	Croflorin B (180)		40.26		
	Croflorin C (181)		25.47		
	Croflorin D (182)		35.78		
	3 α -hydroxy-5,10-didehydrochiliolide (183)		40.58		
<i>Croton laui</i>	3S-acetoxyl-mollotucin D dilactone ester (184)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μ M weak activity	[64]	
	6S-crotoeurin C (185)		1.2		
	Crotoeurin C (186)		1.6		
	Mollotucin D dilactone ester (187)		weak activity		
	Crassifolin F compound 178		weak activity		
<i>Croton poomae</i>	Crotonolide K (188)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μ M 46.43	[65]	
	Furocrotinsulolide A acetate (189)		31.99		
	Furocrotinsulolide A (190)		81.97		
	Compound 191		86.98		
	Compound 192		48.85		
	Crotonolide E (193)		74.78		
	Crotonolide F (194)		42.04		
Compound 195	32.19				

Table 3. Cont.

Plant Source	Compound Name	Methods	Results	References		
<i>Dodonaea viscosa</i>	Hautriwaic acid (196)	Arthritis in mice induced by caolin/carrageenan Doses mg/kg 5 10 20	% inflammation of edema after 15 days 27 20 13	[66]		
		ELISA assay Quantification of IL-10, TNF- α , IL-6 and IL-1 β	Compound 196 diminished TNF- α , IL-6 and IL-1 β and increased IL-10			
<i>Dysoxylum lukii</i>	neoclerod-13Z-ene-3 α , 4 β , 15-triol (197)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μ M. 25.5	[67]		
<i>Jamesoniella autumnalis</i>	Jamesoniellide Q (198)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μ M 45.10	[68]		
	Jamesoniellide R (199)		82.98			
<i>Monoon membranifolium</i>	2 β -Methoxyhardwickiic acid (200)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μ M 65.4	[69]		
	(-)-hardwickiic acid (91)		38.9			
	2 β -acetoxyhardwickiic acid (201)		16.1			
	2 β -hydroxyhardwickiic acid (202)		82.4			
	15-methoxyapatagonic acid (203)		28.9			
<i>Nepeta suaveolens</i>	Nepetolide (204)	Carrageenan-induced hind paw edema Docking Analysis In silico evaluation	Compound 204 inhibited hind paw edema Target Cox-2 EGFR and Lox-2	[70]		
<i>Polyalthia longifolia</i>	16-oxo-cleroda-3,13(14)E-dien-15-oic acid (205)	Cyclooxygenase inhibitory assay 5-LOX kit COX-1 COX-2 5-LOX	IC ₅₀ μ M 8.00 8.41 8.41	[40,71]		
			16-hydroxy-cleroda-3,13-dien-15-oic acid (206)		COX-1 COX-2 5-LOX	9.75 4.07 9.78
					16-hydroxy-cleroda-4(18),13-dien-16,15-olide (74)	COX-1 COX-2 5-LOX
	3 α ,16 α -dihydroxy-cleroda-4(18),13(14)Z-dien-15,16-olide (75)	COX-1 COX-2 5-LOX				3.63 4.29 5.67
		16 α -hydroxy-cleroda-3,13(14)Z-dien-15,16-olide (76)	COX-1 COX-2 5-LOX			3.01 3.29 4.58
			Docking Analysis In silico evaluation		Compounds 74–76 have interactions with COX-1/2 and LOX enzymes	
	3 β -16 α -dihydroxy-cleroda-4(18),13(14)Z-dien-15,16-olide (77)		ELISA assay Quantification of cytokines such as TNF- α , TGF- β , IL-6, IL-10 and IL-1 β		Compounds 74 and 77 inhibited production of proinflammatory cytokines and increased IL-10 and TGF- β	
		Docking Analysis In silico evaluation	Compound 74 docked into the active sites of MDM2, TNF- α , FAK and IL-6 Compound 77 docked into the active sites of MDM2, TNF- α , TGF- β and FAK			
	<i>Scutellaria barbata</i>	Scuttenline C (207)	Griess assay RAW264.7 macrophages stimulated LPS		IC ₅₀ μ M 1.9	[72]
		Barbatin A (208)			12.6	
Scutebarbatine F (209)		3.7				
<i>Teucrium fructicans</i>	11-hydroxyfructicolone (210)	Griess assay RAW264.7 macrophages stimulated LPS	IC ₅₀ μ M 39.3	[73]		

Table 3. Cont.

Plant Source	Compound Name	Methods	Results	References	
<i>Tinospora crispa</i>	Crispinoid D (211)	qPCR assay IL-1 β , IL-6, TNF- α , iNOs, CCL12 and COX-2	Compounds 211–213 diminish the production of pro-inflammatory mediators		
		Luciferase assay: Inhibition of NF- κ B	IC ₅₀ μ M 5.94		
	Tinosporol C (212)	Inhibition of NF- κ B		6.32	
	marrubiagenin-methylester (213)	Inhibition of NF- κ B		25.20	
	Tinopanoid A (214)			IC ₅₀ μ M >60	
	Tinopanoid B (215)			>60	
	Tinopanoid C (216)			24.1	[74,75]
	Tinopanoid D (217)			41.1	
	Tinopanoid E (218)			7.5	
	Tinopanoid F (219)			50.8	
	Tinopanoid G (220)	Griess assay BV-2 cells stimulated LPS		10.6	
	Tinopanoid H (221)			39.4	
	Tinopanoid I (222)			59.1	
	Tinopanoid J (223)			45.9	
	Tinospin C (224)			>60	
borapetol B (225)			>60		
Tinotufolin D (226)			14.5		
<i>Tinospora sagittata</i>	Fibaruretin H (227)	Griess assay RAW264.7 macrophages stimulated LPS	% inhibition at 24 μ M 27.0%	[76]	
	Fibaruretin I (228)		33.1%		

Compound 166 (4*aR*,5*S*,6*R*,8*aR*)-5-[2-(2,5-dihydro-5-methoxy-2-oxofuran-3-yl)ethyl]-3,4,4*a*,5,6,7,8,8*a*-octahydro-5,6,8*a*-trimethylnaphthalene-1-carboxylic acid); Compound 170 (methyl (4*aR*,5*S*,6*R*,8*S*,8*aR*)-3,4,4*a*,5,6,7,8,8*a*-octahydro-8-hydroxy-5,6,8*a*-trimethyl-5-[2-(2-oxo-2,5-dihydrofuran-3-yl)ethyl]naphthalene-1-carboxylate); Compound 173 (3*S*,4*S*,6*S*,8*R*,9*R*,12*S*)-3-acetoxy-18-methoxycarbonyl-6,19:15,16-diepoxy-halim-5(10),13(16),14-triene-20,12-olide; Compound 174 (3*S*,4*S*,6*S*,8*R*,9*R*,12*S*)-3,19-diacetoxy-18-methoxycarbonyl-15,16-epoxy-6-hydroxyhalim-5(10),13(16),14-triene-20,12-olide; Compound 191 (3,4,15,16-diepoxycleroda-13(16),14-diene-12,17-olide); Compound 192 (15,16-epoxy-3 β -hydroxy-5(10),13(16),14-dien-12,17-olide); Compound 195 (3 β ,4 β :15,16-diepoxy-13(16),14-clerodadiene; Compound 226 (2*a* β ,3 α ,5*a* β ,6 β ,7 α ,8*a* α)-6-[2-(3-furanyl)ethyl]-2*a*,3,4,5,5*a*,6,7,8,8*a*,8*b*-decahydro-2*a*,3-dihydroxy-6,7,8*b*-trimethyl-2H-naphtho[1,8-*bc*]furan-2-one). Cells are immortalized by v-raf/v-myc carrying J2 retrovirus (BV-2); inducible nitric oxide synthase (iNOS); cyclooxygenase 2 (COX-2); key sensor molecule in the inflammasome activity (NLRP3); protein found on the surface of some cells that binds epidermal growth factor (EGFR); 5-lipoxygenase (5-LOX); tumor necrosis factor- α (TNF- α); interleukin-6 (IL-6); interleukin 1 β (IL-1 β); proinflammatory-chemokine (C-C motif) ligand 12 (CCL12).




Figure 14. Compounds of *Ajuga pantanthe* and *Callicarpa arborea* with anti-inflammatory activity.




Figure 15. Compounds of *Callicarpa cathayana* and *Callicarpa hypoleucophylla* with anti-inflammatory activity.




Figure 16. Compounds of different species of *Croton* with anti-inflammatory activity.




Figure 17. Compounds of different species of *Croton* with anti-inflammatory activity (continued).




Figure 18. Compounds of *Dodonaea viscosa*, *Dysoxylum lukii*, *Jamesoniella autumnalis*, *Monon membranifolium*, *Nepeta suaveis*, *Polyalthia longifolia* and *Scutellaria barbata* with anti-inflammatory activity.




Figure 19. Compounds of different species of *Teucrium fruticans*, *Tinospora crispa* and *Tinospora sagittata* with anti-inflammatory activity.

2. Discussion

This review discusses research from the last 8 years on clerodane and *neo*-clerodane diterpenes that exhibit cytotoxic and anti-inflammatory activities. It presents studies on these diterpenes with anti-inflammatory effects from 18 species belonging to 7 families and those with cytotoxic activity from 25 species belong to 9 families. These plants mostly belong to the Lamiaceae, Salicaceae, Menispermaceae and Euphorbiaceae families. They include

228 clerodanes and *neo*-clerodanes, of which, 140 have cytotoxic activity, 88 have anti-inflammatory activity and crassifolin Q-U (49–53), compounds 74–77 and (-)-hardwickiic acid (91) have both activities. Compound 75 and 77 were alone in including acute toxicity, but they did not indicate LD₅₀.

2.1. Cytotoxic Activity

All clerodanes included in this review are oxygenated; 58% of them have at least one acetate group, 47% a hydroxyl group, 49% a ring of lactone and 22% a ring of furan as substituents. Additionally, it was found that three diterpenes isolated from *Sheareria nana* (125–127) have -OSO₃H.

We found that 82 compounds out of 140 were evaluated using the MTT assay, which is broadly used to measure the cytotoxic effects of drugs on cancer cell lines, and it is considered a quantitative cytotoxicity analysis; the assay is used more often because in itself, it is relatively straightforward and provides benefits due to the ease of its utility.

Compared to standard cancer therapies, *in vitro* studies have shown the cytotoxic and antiproliferative properties of different clerodane compounds. The mechanisms involved include growth inhibition, apoptosis, interference with DNA synthesis and driving DNA fragmentation in many cancer cell lines of mesenchymal, epithelial and hematopoietic origin [1,3].

Some clerodane compounds inhibit growth in cancer cell lines. Anacolosins A–F (3–8) and corymbulosins X and Y (9–10) isolated from *Anacolosia clarkii* exhibit cytotoxic properties in four paediatric cancer types [21]. Caseakurzin B (29) and caseakurzin J (34) from *Casearia kurzii* were investigated in a lung epithelial carcinoma cell line; the former arrested the cell cycle at the G₂/M phase and the second at the S phase. Obtained from the same plant, corymbulosin M (25), caseamembrin B (26) and caseamembrin U (27) were also cytotoxic in three types of cancer cell lines. Of note, corymbulosin M (25) was the most potent of them and apparently even more active than etoposide, and it was shown that it affects the cell cycle at the G₀/G₁ stage [28]. Kurzipene D (38), also obtained from *C. kurzii*, has a potent antiproliferative effect compared to other kurzipenes and affects proliferation at the S stage. Further, one *in vivo* study used a xenograft tumor model in zebra fish embryos; this compound suppressed tumor proliferation and migration comparable to etoposide [26]. Crassifolins Q–U (49–53) from *Croton crassifolius* inhibited angiogenesis in HUVECs, and crassifolin U (53) had the strongest activity in this model [32]. Notably, the antitumor properties of casearins have been shown using *in vivo* and *ex vivo* methods [30]. Epoxy clerodane diterpene (139) isolated from *Tinospora cordifolia* had cytotoxic activity, inhibiting MCF7 growth by regulating the expression of the functional genes Rb1 and Mdm2 [55].

Several specific antiproliferative mechanisms related to the wide range of clerodanes known today have been described, since many of these compounds have been identified, some which we barely know their properties. It is very possible that there are even more compounds than those described today, in such a way that makes it an open field to discover. However, it is important to mention that clinical studies are required to demonstrate their efficacy in the therapy of the current cancer pandemic, and demonstrating their safety is also of great importance.

2.2. Anti-Inflammatory Activity

A total of 45% of the clerodanes with anti-inflammatory activity have at least one hydroxyl, 69% compounds contain a ring of lactones, 50% a ring of furans and 26% an acetate group as substituents.

We found that 63 compounds reported to have anti-inflammatory activity were evaluated for nitric oxide inhibition with the Griess assay on RAW264.7 macrophages or BV-2-cell-stimulated-LPS, and the clerodanes 157, 158, 185, 186 and 207 showed the best activity in this test with IC₅₀ values of less than 2 μM. In this review, we found that *in vivo* studies have only been performed for hautriwaic acid (196) and nepetolide (204).

The anti-inflammatory activity of clerodane diterpenoids mediated by different mechanisms has been demonstrated in in vitro and in vivo animal models. Compounds **154**, **155**, **157** and **158** from *Callicarpa arborea* showed potent inhibitory effects against the NLRP3 inflammasome by inhibiting Casp-1 activation and IL-1 β in reticulum cell sarcoma cells [59].

Clerodane **74–77** and **206** from extracts of *Polyalthia longifolia* seeds inhibit inflammation, blocking the synthesis of prostaglandins and leukotrienes through highly selective binding to cyclooxygenases (COX) 1 and 2 and 5-lipoxygenase (5-LOX), respectively, compared to the nonsteroidal anti-inflammatory drugs diclofenac and indomethacin [71]. In 2008, clerodane **206** was associated with the suppression of neutrophil respiratory burst and degranulation, and it is thought that it is mediated at least in part by the inhibition of calcium mobilization, AKT (protein kinase B) and p38 mitogen-activated protein kinase pathways [77]. Hautriwaic acid (**196**) from *Dodonaea viscosa* leaves, used for rheumatism, exhibited anti-inflammatory activity in a mouse ear edema model [66]. Clerodane compounds **164–175** from *Callicarpa hypoleucophylla* suppress superoxide anion generation and elastase release, inhibiting the function of human neutrophils [61]. *Trans*-crotonin inhibits dextran- and histamine-induced oedema [2].

Compounds derived from the *Scutellaria* genus have strong interactions with inducible nitric oxide synthase, and because of that, they inhibit nitric oxide production [72]. Five clerodane diterpenoids from *Croton crassifolius* roots, named crassifolins Q–U (**49–53**), reduced the levels of IL-6 and TNF- α in lipopolysaccharide-stimulated RAW 264.7 cells [32]. Compounds **211–213** from *Tinospora crispa* diminish the production of pro-inflammatory mediators (IL-1 β , IL-6, TNF- α , iNOs, CCL12 and COX-2) [74].

3. Conclusions

In summary, clerodane diterpenes have activity against different cell cancer lines. Furthermore, some of the diterpenes presented in this review have already-known therapeutic targets, and therefore, their potential adverse effects can be predicted in some way, but the discovery of new compounds and new mechanisms remains to be seen. Anyway, the study of possible new therapies for inflammation continues to be important in order to expand the options for the treatment of inflammatory diseases that afflict the world.

More than 50% of clerodanes included in this review with cytotoxic activity contain acetate groups; on the other hand, 69% of the compounds with anti-inflammatory effects have a ring of lactone.

Author Contributions: Conceptualization, J.P.-R. and S.P.-G.; methodology, R.M.M.-C., L.H.-V., A.M., L.S.-P., S.P.-G. and J.P.-R.; validation R.M.M.-C., L.H.-V., A.M., L.S.-P., S.P.-G. and J.P.-R.; formal analysis, R.M.M.-C., L.H.-V., A.M., L.S.-P., S.P.-G. and J.P.-R.; data curation, R.M.M.-C., L.H.-V., A.M., L.S.-P., S.P.-G. and J.P.-R.; writing—original draft preparation, S.P.-G. and A.M.; writing—review and editing, R.M.M.-C., L.H.-V., A.M., L.S.-P., S.P.-G. and J.P.-R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Acquaviva, R.; Malfa, G.A.; Loizzo, M.R.; Xiao, J.; Bianchi, S.; Tundis, R. Advances on Natural Abietane, Labdane and Clerodane Diterpenes as Anti-Cancer Agents: Sources and Mechanisms of Action. *Molecules* **2022**, *27*, 4791. [[CrossRef](#)] [[PubMed](#)]
2. Feng, Z.; Cao, J.; Zhang, Q.; Lin, L. The Drug Likeness Analysis of Anti-Inflammatory Clerodane Diterpenoids. *Chin. Med.* **2020**, *15*, 126. [[CrossRef](#)] [[PubMed](#)]
3. Li, R.; Morris-Natschke, S.L.; Lee, K.-H. Clerodane Diterpenes: Sources, Structures, and Biological Activities. *Nat. Prod. Rep.* **2016**, *33*, 1166–1226. [[CrossRef](#)] [[PubMed](#)]

4. dos Lima, J.; Marinho, E.M.; Alencar de Menezes, J.E.; Mendes, F.R.S.; da Silva Antonio, W.; Maria, K.A.F.; Emmanuel, S.M.; Marinho, M.M.; Bandeira, P.N.; dos Santos, H.S. Biological Properties of Clerodane-Type Diterpenes. *J. Anal. Pharm. Res.* **2022**, *11*, 56–64. [[CrossRef](#)]
5. Kumar, A.; Shukla, R.; Chaudhary, A. Evaluation of Antiulcerogenic Activity of Clerodendron Infortunatum Extract on Albino Rat Gastric Ulceration. *J. Drug Deliv. Ther.* **2019**, *9*, 57–62. [[CrossRef](#)]
6. Ranganathan, M.; Schnakenberg, A.; Skosnik, P.D.; Cohen, B.M.; Pittman, B.; Sewell, R.A.; D'Souza, D.C. Dose-Related Behavioral, Subjective, Endocrine, and Psychophysiological Effects of the κ Opioid Agonist Salvinorin A in Humans. *Biol. Psychiatry* **2012**, *72*, 871–879. [[CrossRef](#)]
7. Cichon, J.; Liu, R.; Le, H.V. Therapeutic Potential of Salvinorin A and Its Analogues in Various Neurological Disorders. *Transl. Perioper. Pain Med.* **2022**, *9*, 452–457.
8. Jiang, H.; Zhang, G.-J.; Liu, Y.-F.; Wang, H.-S.; Liang, D. Clerodane Diterpenoid Glucosides from the Stems of *Tinospora sinensis*. *J. Nat. Prod.* **2017**, *80*, 975–982. [[CrossRef](#)]
9. Tokoroyama, T. Synthesis of Clerodane Diterpenoids and Related Compounds—Stereoselective Construction of the Decalin Skeleton with Multiple Contiguous Stereogenic Centers. *Synthesis* **2000**, *2000*, 611–633. [[CrossRef](#)]
10. Hagiwara, H. Total Syntheses of Clerodane Diterpenoids—A Review. *Nat. Prod. Commun.* **2019**, *14*, 1934578X19843613. [[CrossRef](#)]
11. Soerjomataram, I.; Bray, F. Planning for Tomorrow: Global Cancer Incidence and the Role of Prevention 2020–2070. *Nat. Rev. Clin. Oncol.* **2021**, *18*, 663–672. [[CrossRef](#)] [[PubMed](#)]
12. Tsimberidou, A.M.; Fountzilias, E.; Nikanjam, M.; Kurzrock, R. Review of Precision Cancer Medicine: Evolution of the Treatment Paradigm. *Cancer Treat. Rev.* **2020**, *86*, 102019. [[CrossRef](#)] [[PubMed](#)]
13. Wang, H.; He, Y.; Jian, M.; Fu, X.; Cheng, Y.; He, Y.; Fang, J.; Li, L.; Zhang, D. Breaking the Bottleneck in Anticancer Drug Development: Efficient Utilization of Synthetic Biology. *Molecules* **2022**, *27*, 7480. [[CrossRef](#)] [[PubMed](#)]
14. Gallego-Jara, J.; Lozano-Terol, G.; Sola-Martínez, R.A.; Cánovas-Díaz, M.; de Diego Puente, T. A Compressive Review about Taxol[®]: History and Future Challenges. *Molecules* **2020**, *25*, 5986. [[CrossRef](#)]
15. Li, D.; Xue, M.; Geng, Z.; Chen, P. The Suppressive Effects of Bursopentine (BP5) on Oxidative Stress and NF- κ B Activation in Lipopolysaccharide-Activated Murine Peritoneal Macrophages. *Cell Physiol. Biochem.* **2012**, *29*, 9–20. [[CrossRef](#)] [[PubMed](#)]
16. Pahwa, R.; Goyal, A.; Jialal, I. *Chronic Inflammation*; StatPearls Publishing: Treasure Island, FL, USA, 2022.
17. Nathan, C.; Ding, A. Nonresolving Inflammation. *Cell* **2010**, *140*, 871–882. [[CrossRef](#)] [[PubMed](#)]
18. Fuller, B. Role of PGE-2 and Other Inflammatory Mediators in Skin Aging and Their Inhibition by Topical Natural Anti-Inflammatories. *Cosmetics* **2019**, *6*, 6. [[CrossRef](#)]
19. Araruna, M.E.; Serafim, C.; Alves Júnior, E.; Hiruma-Lima, C.; Diniz, M.; Batista, L. Intestinal Anti-Inflammatory Activity of Terpenes in Experimental Models (2010–2020): A Review. *Molecules* **2020**, *25*, 5430. [[CrossRef](#)]
20. Olatunde, O.Z.; Yong, J.; Lu, C. New Neo-Clerodane Diterpenoids Isolated from *Ajuga decumbens* Thunb., Planted at Pingtan Island of Fujian Province with the Potent Anticancer Activity. *Anti-Cancer Agents Med. Chem.* **2023**, *23*, 237–244.
21. Cai, S.; Risinger, A.L.; Petersen, C.L.; Grkovic, T.; O'Keefe, B.R.; Mooberry, S.L.; Cichewicz, R.H. Anacolosins A-F and Corymbulosins X and Y, Clerodane Diterpenes from *Anacolosia clarkii* Exhibiting Cytotoxicity toward Pediatric Cancer Cell Lines. *J. Nat. Prod.* **2019**, *82*, 928–936. [[CrossRef](#)]
22. Vila-Luna, M.L.; Moo-Puc, R.E.; Torres-Tapia, L.W.; Peraza-Sánchez, S.R. Cytotoxic Activity of Casearborin c Isolated from *Casearia corymbosa*. *J. Mex. Chem Soc.* **2018**, *62*, 24–28. [[CrossRef](#)]
23. Meesakul, P.; Ritthiwigrom, T.; Cheenpracha, S.; Sripisut, T.; Maneerat, W.; Machan, T.; Laphookhieo, S. A New Cytotoxic Clerodane Diterpene from *Casearia graveolens* Twigs. *Nat. Prod. Commun.* **2016**, *11*, 13–15. [[CrossRef](#)]
24. Nuanyai, T.; Chailap, B.; Buakeaw, A.; Puthong, S. Cytotoxicity of Clerodane Diterpenoids from Fresh Ripe Fruits of *Casearia grewiifolia*. *J. Sci. Technol.* **2017**, *39*, 517–521. [[CrossRef](#)]
25. Nguyen, H.T.T.; Truong, N.B.; Doan, H.T.M.; Litaudon, M.; Retailleau, P.; Do, T.T.; Nguyen, H.V.; Chau, M.V.; Pham, C.V. Cytotoxic Clerodane Diterpenoids from the Leaves of *Casearia grewiifolia*. *J. Nat. Prod.* **2015**, *78*, 2726–2730. [[CrossRef](#)]
26. Liang, Y.; Zhang, Q.; Yang, X.; Li, Y.; Zhang, X.; Li, Y.; Du, Q.; Jin, D.-Q.; Cui, J.; Lall, N.; et al. Diterpenoids from the Leaves of *Casearia kurzii* Showing Cytotoxic Activities. *Bioorg. Chem.* **2020**, *98*, 103741. [[CrossRef](#)]
27. Zhang, L.-T.; Wang, X.-L.; Wang, T.; Zhang, J.-S.; Huang, Z.-Q.; Shen, T.; Lou, H.-X.; Ren, D.-M.; Wang, X.-N. Dolabellane and Clerodane Diterpenoids from the Twigs and Leaves of *Casearia kurzii*. *J. Nat. Prod.* **2020**, *83*, 2817–2830. [[CrossRef](#)]
28. Shuo, Y.; Zhang, C.; Yang, X.; Liu, F.; Zhang, Q.; Li, A.; Ma, J.; Lee, D.; Ohizumi, Y.; Guo, Y. Clerodane Diterpenoids from *Casearia kurzii* and Their Cytotoxic Activities. *J. Nat. Med.* **2019**, *73*, 826–833. [[CrossRef](#)]
29. Liu, F.; Zhang, Q.; Yang, X.; Xi, Y.; Zhang, X.; Wang, H.; Zhang, J.; Tuerhong, M.; Jin, D.-Q.; Lee, D.; et al. Cytotoxic Diterpenoids as Potential Anticancer Agents from the Twigs of *Casearia kurzii*. *Bioorg. Chem.* **2019**, *89*, 102995. [[CrossRef](#)]
30. Ferreira, P.M.P.; Bezerra, D.P.; do Nascimento Silva, J.; da Costa, M.P.; de Oliveira Ferreira, J.R.; Alencar, N.M.N.; de Figueiredo, I.S.T.; Cavalheiro, A.J.; Machado, C.M.L.; Chammas, R.; et al. Preclinical Anticancer Effectiveness of a Fraction from *Casearia Sylvestris* and Its Component Casearin X: In Vivo and Ex Vivo Methods and Microscopy Examinations. *J. Ethnopharmacol.* **2016**, *186*, 270–279. [[CrossRef](#)]
31. Zou, M.-F.; Pan, Y.-H.; Hu, R.; Yuan, F.-Y.; Huang, D.; Tang, G.-H.; Li, W.; Yin, S. Highly Modified Nor-Clerodane Diterpenoids from *Croton yanhuui*. *Fitoterapia* **2021**, *153*, 104979. [[CrossRef](#)]

32. Li, C.; Sun, X.; Yin, W.; Zhan, Z.; Tang, Q.; Wang, W.; Zhuo, X.; Wu, Z.; Zhang, H.; Li, Y.; et al. Crassifolins Q–W: Clerodane Diterpenoids From *Croton crassifolius* With Anti-Inflammatory and Anti-Angiogenesis Activities. *Front. Chem.* **2021**, *9*, 733350. [[CrossRef](#)]
33. Tian, J.-L.; Yao, G.-D.; Wang, Y.-X.; Gao, P.-Y.; Wang, D.; Li, L.-Z.; Lin, B.; Huang, X.-X.; Song, S.-J. Cytotoxic Clerodane Diterpenoids from *Croton crassifolius*. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 1237–1242. [[CrossRef](#)] [[PubMed](#)]
34. Qiu, M.; Cao, D.; Gao, Y.; Li, S.; Zhu, J.; Yang, B.; Zhou, L.; Zhou, Y.; Jin, J.; Zhao, Z. New Clerodane Diterpenoids from *Croton crassifolius*. *Fitoterapia* **2016**, *108*, 81–86. [[CrossRef](#)] [[PubMed](#)]
35. Vendruscolo, I.; Venturella, S.R.T.; Bressiani, P.A.; Marco, I.G.; Novello, C.R.; Almeida, I.V.; Vicentini, V.E.P.; Mello, J.C.P.; Düsman, E. Cytotoxicity of Extracts and Compounds Isolated from *Croton echioides* in Animal Tumor Cell (HTC). *Braz. J. Biol.* **2022**, *82*, e264356. [[CrossRef](#)] [[PubMed](#)]
36. Guetchueng, S.T.; Nahar, L.; Ritchie, K.J.; Ismail, F.M.D.; Evans, A.R.; Sarker, S.D. Ent-Clerodane Diterpenes from the Bark of *Croton oligandrus* Pierre Ex Hutch. and Assessment of Their Cytotoxicity against Human Cancer Cell Lines. *Molecules* **2018**, *23*, 410. [[CrossRef](#)]
37. Ng, S.-Y.; Kamada, T.; Suleiman, M.; Vairappan, C.S. Two New Clerodane-Type Diterpenoids from Bornean Liverwort *Gottschelia schizophleura* and Their Cytotoxic Activity. *Nat. Prod. Res.* **2018**, *32*, 1832–1837. [[CrossRef](#)]
38. Aimaiti, S.; Suzuki, A.; Saito, Y.; Fukuyoshi, S.; Goto, M.; Miyake, K.; Newman, D.J.; O’Keefe, B.R.; Lee, K.-H.; Nakagawa-Goto, K. Corymbulins I–W, Cytotoxic Clerodane Diterpenes from the Bark of *Laetia corymbulosa*. *J. Org. Chem.* **2018**, *83*, 951–963. [[CrossRef](#)] [[PubMed](#)]
39. Widyowati, R.; Sugimoto, S.; Yamano, Y.; Sukardiman; Otsuka, H.; Matsunami, K. New Cis-Ent-Clerodanes from *Linaria japonica*. *Phytochem. Lett.* **2015**, *14*, 56–62. [[CrossRef](#)]
40. Tatipamula, V.B.; Thonangi, C.V.; Dakal, T.C.; Vedula, G.S.; Dhabhai, B.; Polimati, H.; Akula, A.; Nguyen, H.T. Potential Anti-Hepatocellular Carcinoma Properties and Mechanisms of Action of Clerodane Diterpenes Isolated from *Polyalthia longifolia* Seeds. *Sci. Rep.* **2022**, *12*, 9267. [[CrossRef](#)]
41. Yu, Z.-X.; Fu, Y.-H.; Chen, G.-Y.; Song, X.-P.; Han, C.-R.; Li, X.-B.; Song, X.-M.; Wu, A.-Z.; Chen, S.-C. New Clerodane Diterpenoids from the Roots of *Polyalthia laui*. *Fitoterapia* **2016**, *111*, 36–41. [[CrossRef](#)]
42. Bautista, E.; Fragoso-Serrano, M.; Ortiz-Pastrana, N.; Toscano, R.A.; Ortega, A. Structural Elucidation and Evaluation of Multidrug-Resistance Modulatory Capability of Amarisinins A–C, Diterpenes Derived from *Salvia amarissima*. *Fitoterapia* **2016**, *114*, 1–6. [[CrossRef](#)] [[PubMed](#)]
43. Fragoso-Serrano, M.; Ortiz-Pastrana, N.; Luna-Cruz, N.; Toscano, R.A.; Alpuche-Solís, A.G.; Ortega, A.; Bautista, E. Amarisolide F, an Acylated Diterpenoid Glucoside and Related Terpenoids from *Salvia amarissima*. *J. Nat. Prod.* **2019**, *82*, 631–635. [[CrossRef](#)]
44. Bautista, E.; Fragoso-Serrano, M.; Toscano, R.A.; García-Peña, M.d.R.; Ortega, A. Teotihuacanin, a Diterpene with an Unusual Spiro-10/6 System from *Salvia amarissima* with Potent Modulatory Activity of Multidrug Resistance in Cancer Cells. *Org. Lett.* **2015**, *17*, 3280–3282. [[CrossRef](#)] [[PubMed](#)]
45. Bustos-Brito, C.; Pérez-Juanchi, D.; Rivera-Chávez, J.; Hernández-Herrera, A.D.; Bedolla-García, B.Y.; Zamudio, S.; Ramírez-Apan, T.; Quijano, L.; Esquivel, B. Clerodane and 5 10-Seco-Clerodane-Type Diterpenoids from *Salvia involucrata*. *J. Mol. Struct.* **2021**, *1237*, 130367. [[CrossRef](#)]
46. Jiang, Y.-J.; Su, J.; Shi, X.; Wu, X.-D.; Chen, X.-Q.; He, J.; Shao, L.-D.; Li, X.-N.; Peng, L.-Y.; Li, R.-T.; et al. Neo-Clerodanes from the Aerial Parts of *Salvia leucantha*. *Tetrahedron* **2016**, *72*, 5507–5514. [[CrossRef](#)]
47. Wang, M.; Chen, Y.; Hu, P.; Ji, J.; Li, X.; Chen, J. Neoclerodane Diterpenoids from *Scutellaria barbata* with Cytotoxic Activities. *Nat. Prod. Res.* **2020**, *34*, 1345–1351. [[CrossRef](#)]
48. Yang, G.-C.; Hu, J.-H.; Li, B.-L.; Liu, H.; Wang, J.-Y.; Sun, L.-X. Six New Neo-Clerodane Diterpenoids from Aerial Parts of *Scutellaria barbata* and Their Cytotoxic Activities. *Planta Med.* **2018**, *84*, 1292–1299. [[CrossRef](#)]
49. Yuan, Q.-Q.; Song, W.-B.; Wang, W.-Q.; Xuan, L.-J. Scubatines A–F, New Cytotoxic Neo-Clerodane Diterpenoids from *Scutellaria barbata* D. Don. *Fitoterapia* **2017**, *119*, 40–44. [[CrossRef](#)]
50. Wang, M.; Ma, C.; Chen, Y.; Li, X.; Chen, J. Cytotoxic Neo-Clerodane Diterpenoids from *Scutellaria barbata* D. Don. *Chem. Biodivers.* **2019**, *16*, e1800499. [[CrossRef](#)]
51. Dai, S.-J.; Xiao, K.; Zhang, L.; Han, Q.-T. New Neo-Clerodane Diterpenoids from *Scutellaria strigillosa* with Cytotoxic Activities. *J. Asian Nat. Prod. Res.* **2016**, *18*, 456–461. [[CrossRef](#)]
52. Dai, S.-J.; Zhang, L.; Xiao, K.; Han, Q.-T. New Cytotoxic Neo-Clerodane Diterpenoids from *Scutellaria strigillosa*. *Bioorg. Med. Chem. Lett.* **2016**, *26*, 1750–1753. [[CrossRef](#)] [[PubMed](#)]
53. Tang, Z.; Shen, J.; Zhang, F.; Liang, J.; Xia, Z. Sulfated Neo-Clerodane Diterpenoids and Triterpenoid Saponins from *Sheareria nana* S. Moore. *Fitoterapia* **2018**, *124*, 12–16. [[CrossRef](#)] [[PubMed](#)]
54. Wang, B.; Zhang, P.-L.; Zhou, M.-X.; Shen, T.; Zou, Y.-X.; Lou, H.-X.; Wang, X.-N. New Nor-Clerodane-Type Furanoditerpenoids from the Rhizomes of *Tinospora capillipes*. *Phytochem. Lett.* **2016**, *15*, 225–229. [[CrossRef](#)]
55. Subash-Babu, P.; Alshammari, G.M.; Ignacimuthu, S.; Alshatwi, A.A. Epoxy Clerodane Diterpene Inhibits MCF-7 Human Breast Cancer Cell Growth by Regulating the Expression of the Functional Apoptotic Genes Cdkn2A, Rb1, Mdm2 and P53. *Biomed. Pharmacother.* **2017**, *87*, 388–396. [[CrossRef](#)]
56. Qin, N.; Wang, A.; Li, D.; Wang, K.; Lin, B.; Li, Z.; Hua, H. Cytotoxic Clerodane Furanoditerpenoids from the Root of *Tinospora sagittata*. *Phytochem. Lett.* **2015**, *12*, 173–176. [[CrossRef](#)]

57. Liu, W.; Song, Z.; Wang, H.; Yang, X.; Joubert, E.; Zhang, J.; Li, S.; Tuerhong, M.; Abudukeremu, M.; Jin, J.; et al. Diterpenoids as Potential Anti-Inflammatory Agents from *Ajuga pantanthera*. *Bioorg. Chem.* **2020**, *101*, 103966. [[CrossRef](#)]
58. Dong, B.; Yang, X.; Liu, W.; An, L.; Zhang, X.; Tuerhong, M.; Du, Q.; Wang, C.; Abudukeremu, M.; Xu, J.; et al. Anti-Inflammatory Neo-Clerodane Diterpenoids from *Ajuga pantanthera*. *J. Nat. Prod.* **2020**, *83*, 894–904. [[CrossRef](#)]
59. Pu, D.-B.; Zhang, X.-J.; Bi, D.-W.; Gao, J.-B.; Yang, Y.; Li, X.-L.; Lin, J.; Li, X.-N.; Zhang, R.-H.; Xiao, W.-L. Callicarpins, Two Classes of Rearranged Ent-Clerodane Diterpenoids from *Callicarpa* Plants Blocking NLRP3 Inflammasome-Induced Pyroptosis. *J. Nat. Prod.* **2020**, *83*, 2191–2199. [[CrossRef](#)]
60. Wang, Y.; Lin, J.; Wang, Q.; Shang, K.; Pu, D.-B.; Zhang, R.-H.; Li, X.-L.; Dai, X.-C.; Zhang, X.-J.; Xiao, W.-L. Clerodane Diterpenoids with Potential Anti-Inflammatory Activity from the Leaves and Twigs of *Callicarpa cathayana*. *Chin. J. Nat. Med.* **2019**, *17*, 953–962. [[CrossRef](#)]
61. Lin, Y.-C.; Lin, J.-J.; Chen, S.-R.; Hwang, T.-L.; Fang, S.-Y.; Korinek, M.; Chen, C.-Y.; Lin, Y.-S.; Wu, T.-Y.; Yen, M.-H.; et al. Clerodane Diterpenoids from *Callicarpa hypoleucophylla* and Their Anti-Inflammatory Activity. *Molecules* **2020**, *25*, 2288. [[CrossRef](#)]
62. Ye, G.-H.; Xue, J.-J.; Liang, W.-L.; Yang, S.-J. Three New Bioactive Diterpenoids from the Roots of *Croton crassifolius*. *Nat. Prod. Res.* **2021**, *35*, 1421–1427. [[CrossRef](#)] [[PubMed](#)]
63. Queiroz, S.A.S.; Pinto, M.E.F.; Bobey, A.F.; Russo, H.M.; Batista, A.N.L.; Batista, J.M.; Codo, A.C.; Medeiros, A.I.; Bolzani, V.S. Diterpenoids with Inhibitory Activity of Nitrite Production from *Croton floribundus*. *J. Ethnopharmacol.* **2020**, *249*, 112320. [[CrossRef](#)]
64. Li, F.; Zhang, D.-B.; Li, J.-T.; He, F.-J.; Zhu, H.-L.; Li, N.; Xiao, X.-C.; Ren, L.; Zheng, W. Bioactive Terpenoids from *Croton laui*. *Nat. Prod. Res.* **2021**, *35*, 2849–2857. [[CrossRef](#)]
65. Somteds, A.; Tantapakul, C.; Kanokmedhakul, K.; Laphookhieo, S.; Phukhatmuen, P.; Kanokmedhakul, S. Inhibition of Nitric Oxide Production by Clerodane Diterpenoids from Leaves and Stems of *Croton poomae* Esser. *Nat. Prod. Res.* **2021**, *35*, 2722–2729. [[CrossRef](#)]
66. Salinas-Sánchez, D.O.; Zamilpa, A.; Pérez, S.; Herrera-Ruiz, M.; Tortoriello, J.; González-Cortazar, M.; Jiménez-Ferrer, E. Effect of Hautriwaic Acid Isolated from *Dodonaea viscosa* in a Model of Kaolin/Carrageenan-Induced Monoarthritis. *Planta Med.* **2015**, *81*, 1240–1247. [[CrossRef](#)]
67. Zhang, P.-Z.; Zhang, Y.-M.; Lin, Y.; Wang, F.; Zhang, G.-L. Three New Diterpenes from *Dysoxylum lukii* and Their NO Production Inhibitory Activity. *J. Asian Nat. Prod. Res.* **2020**, *22*, 531–536. [[CrossRef](#)]
68. Li, Y.; Zhu, R.; Zhang, J.; Wu, X.; Shen, T.; Zhou, J.; Qiao, Y.; Gao, Y.; Lou, H. Clerodane Diterpenoids from the Chinese Liverwort *Jamesoniella autumnalis* and Their Anti-Inflammatory Activity. *Phytochemistry* **2018**, *154*, 85–93. [[CrossRef](#)]
69. Polbuppha, I.; Suthiphasilp, V.; Maneerat, T.; Charoensup, R.; Limtharakul, T.; Cheenpracha, S.; Pyne, S.G.; Laphookhieo, S. Nitric Oxide Production Inhibitory Activity of Clerodane Diterpenes from *Monoon membranifolium*. *Nat. Prod. Res.* **2022**, *36*, 2513–2517. [[CrossRef](#)]
70. ur Rehman, T.; Khan, A.; Abbas, A.; Hussain, J.; Khan, F.U.; Stieglitz, K.; Ali, S. Investigation of Nepetolide as a Novel Lead Compound: Antioxidant, Antimicrobial, Cytotoxic, Anticancer, Anti-Inflammatory, Analgesic Activities and Molecular Docking Evaluation. *Saudi Pharm. J.* **2018**, *26*, 422–429. [[CrossRef](#)]
71. Nguyen, H.T.; Vu, T.-Y.; Chandi, V.; Polimati, H.; Tatipamula, V.B. Dual COX and 5-LOX Inhibition by Clerodane Diterpenes from Seeds of *Polyalthia longifolia* (Sonn.) Thwaites. *Sci. Rep.* **2020**, *10*, 15965. [[CrossRef](#)]
72. Feng, X.-S.; Yan, W.; Bai, L.-H.; Wang, K.; Chen, X.-Q. Neo-Clerodane Diterpenoids from the Aerial Parts of *Scutellaria barbata* with Anti-Inflammatory Activity. *Chem. Biodivers.* **2021**, *18*, e2100693. [[CrossRef](#)] [[PubMed](#)]
73. Lv, H.-W.; Luo, J.-G.; Zhu, M.-D.; Zhao, H.-J.; Kong, L.-Y. Neo-Clerodane Diterpenoids from the Aerial Parts of *Teucrium fruticans* Cultivated in China. *Phytochemistry* **2015**, *119*, 26–31. [[CrossRef](#)] [[PubMed](#)]
74. You, J.-Q.; Liu, Y.-N.; Zhou, J.-S.; Sun, X.-Y.; Lei, C.; Mu, Q.; Li, J.-Y.; Hou, A.-J. Cis-Clerodane Diterpenoids with Structural Diversity and Anti-Inflammatory Activity from *Tinospora crispa*. *Chin. J. Chem.* **2022**, *40*, 2882–2892. [[CrossRef](#)]
75. Zhu, Y.-L.; Deng, L.; Song, J.-Q.; Zhu, Y.; Yuan, R.-W.; Fan, X.-Z.; Zhou, H.; Huang, Y.-S.; Zhang, L.-J.; Liao, H.-B. Clerodane Diterpenoids with Anti-Inflammatory and Synergistic Antibacterial Activities from *Tinospora crispa*. *Org. Chem. Front.* **2022**, *9*, 6945–6957. [[CrossRef](#)]
76. Zhang, G.; Ma, H.; Hu, S.; Xu, H.; Yang, B.; Yang, Q.; Xue, Y.; Cheng, L.; Jiang, J.; Zhang, J.; et al. Clerodane-Type Diterpenoids from Tuberos Roots of *Tinospora sagittata* (Oliv.) Gagnep. *Fitoterapia* **2016**, *110*, 59–65. [[CrossRef](#)]
77. Chang, H.-L.; Chang, F.-R.; Chen, J.-S.; Wang, H.-P.; Wu, Y.-H.; Wang, C.-C.; Wu, Y.-C.; Hwang, T.-L. Inhibitory Effects of 16-Hydroxycleroda-3,13(14)E-Dien-15-Oic Acid on Superoxide Anion and Elastase Release in Human Neutrophils through Multiple Mechanisms. *Eur. J. Pharmacol.* **2008**, *586*, 332–339. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.